Achillion Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ACHN, Achillion Pharmaceuticals Inc, priceseries

Achillion Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
6.98
Close
6.76
High
7.01
Low
6.75
Previous Close
6.13
Daily Price Gain
0.63
YTD High
7.01
YTD High Date
Jan 27, 2020
YTD Low
6.03
YTD Low Date
Jan 2, 2020
YTD Price Change
0.69
YTD Gain
11.37%
52 Week High
7.01
52 Week High Date
Jan 27, 2020
52 Week Low
2.35
52 Week Low Date
Jul 18, 2019
52 Week Price Change
4.10
52 Week Gain
154.14%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 27. 2017
4.37
Oct 11. 2017
4.59
10 Trading Days
5.03%
Link
LONG
Mar 1. 2018
3.32
Mar 16. 2018
3.93
11 Trading Days
18.23%
Link
LONG
Aug 21. 2018
2.63
Sep 13. 2018
3.27
16 Trading Days
24.37%
Link
LONG
Jan 4. 2019
1.80
Jan 22. 2019
2.11
11 Trading Days
17.37%
Link
LONG
Feb 8. 2019
2.22
Mar 22. 2019
2.98
29 Trading Days
34.35%
Link
LONG
Jul 22. 2019
2.77
Aug 20. 2019
4.63
21 Trading Days
67.24%
Link
Company Information
Stock Symbol
ACHN
Exchange
NasdaqGS
Company URL
http://www.achillion.com
Company Phone
203-624-7000
CEO
Milind S. Deshpande
Headquarters
Connecticut
Business Address
300 GEORGE STREET, NEW HAVEN, CT 06511
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001070336
About

Achillion Pharmaceuticals, Inc. engages in the research and development of small molecule drug therapies for infectious diseases and immune system disorders. It intends to commercialize its anti-viral medicines for the treatment of hepatitis C and resistant bacterial infections. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

Description

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading